Alvotech Rises After FDA Accepts Biosimilar Application for Entyvio Alternative https://t.co/iHbSG41Vtl • Alvotech shares gained 7% after the FDA accepted for review its Biologics License Application for AVT16, a proposed biosimilar to Entyvio. • AVT16 is being developed to treat ulcerative colitis and Crohn's disease and is being commercialized in partnership with Teva Pharmaceutical. • The company is seeking interchangeable status, which could allow pharmacists to substitute AVT16 for the reference product without requiring physician approval, subject to state regulations. • FDA acceptance marks an important regulatory milestone and moves the product closer to potential commercialization in the U.S. market. • Investors see the development as a positive step in expanding Alvotech's biosimilar portfolio and strengthening its presence in the fast-growing immunology and gastrointestinal treatment markets. Explore Category https://t.co/E6F6hmdC8B $ALVO $TEVA $TAK $ABBV